BlackRock Inc. Invests $5.03 Million in Nautilus Biotechnology, Inc. $NAUT

Key Points

• BlackRock acquired 2.69 million shares of Nautilus Biotechnology in the second quarter, worth approximately $5.03 million and representing about 2.11% of the company.
• Institutional ownership remains significant at 50.71%, with several other funds recently establishing or expanding positions in NAUT.
• Analyst sentiment is mixed: the stock carries a consensus “Hold” rating with a $4.00 price target, while shares recently traded near $0.90 and Weiss Ratings downgraded the company to “sell.”

BlackRock Inc. bought a new position in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,687,226 shares of the company's stock, valued at approximately $5,025,000. BlackRock Inc. owned about 2.11% of Nautilus Biotechnology as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of NAUT. Garde Capital Inc. bought a new stake in Nautilus Biotechnology in the 4th quarter valued at $35,000. Hudson Bay Capital Management LP bought a new position in shares of Nautilus Biotechnology during the 4th quarter valued at about $37,000. Qube Research & Technologies Ltd purchased a new position in shares of Nautilus Biotechnology during the second quarter valued at about $45,000. Virtu Financial LLC grew its position in shares of Nautilus Biotechnology by 19.6% during the fourth quarter. Virtu Financial LLC now owns 23,532 shares of the company's stock valued at $46,000 after purchasing an additional 3,849 shares in the last quarter. Finally, CTC Alternative Strategies Ltd. bought a new stake in shares of Nautilus Biotechnology in the first quarter worth about $48,000. 50.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered Nautilus Biotechnology from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Nautilus Biotechnology presently has an average rating of "Hold" and a consensus price target of $4.00.

Nautilus Biotechnology Stock Down 1.6%

Shares of Nautilus Biotechnology stock opened at $0.90 on Friday. The company has a market capitalization of $115.15 million, a PE ratio of -2.01 and a beta of 0.87. Nautilus Biotechnology, Inc. has a 52 week low of $0.65 and a 52 week high of $4.31. The stock's fifty day moving average is $1.28 and its two-hundred day moving average is $2.22.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. The business had revenue of $0.19 million during the quarter, compared to analysts' expectations of $0.10 million.

Nautilus Biotechnology Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.

Want to see what other hedge funds are holding NAUT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.